Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
572
mi
from
Houston, TX
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
572
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
1174
mi
from
Hampton, VA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
1174
mi
from
Hampton, VA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
8648
mi
from
Darlinghurst,
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
8648
mi
from
Darlinghurst,
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
UCDavis Research Office at CARES
1283
mi
from
Sacramento, CA
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
UCDavis Research Office at CARES
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
Jacobi & North Central Bronx Hospitals
1295
mi
from
Bronx, NY
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
Jacobi & North Central Bronx Hospitals
1295
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
AIDS Clinical Trials Unit
1045
mi
from
Chapel Hill, NC
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
AIDS Clinical Trials Unit
1045
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice
1225
mi
from
Philadelphia, PA
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated:  1/23/2017
The Ottawa Hospital
1255
mi
from
Ottawa,
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status: Enrolling
Updated: 1/23/2017
The Ottawa Hospital
1255
mi
from
Ottawa,
Click here to add this to my saved trials
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated:  1/23/2017
Alabama CRS
683
mi
from
Birmingham, AL
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated: 1/23/2017
Alabama CRS
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated:  1/23/2017
Bridge HIV CRS
1341
mi
from
San Francisco, CA
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated: 1/23/2017
Bridge HIV CRS
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated:  1/23/2017
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
1442
mi
from
Boston, MA
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated: 1/23/2017
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
1442
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated:  1/23/2017
University of Rochester Vaccines to Prevent HIV Infection CRS
1121
mi
from
Rochester, NY
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants
Status: Enrolling
Updated: 1/23/2017
University of Rochester Vaccines to Prevent HIV Infection CRS
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
HIV Non-Occupational Post-Exposure Prophylaxis
A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Status: Enrolling
Updated:  1/25/2017
Fenway Community Health
1444
mi
from
Boston, MA
HIV Non-Occupational Post-Exposure Prophylaxis
A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Status: Enrolling
Updated: 1/25/2017
Fenway Community Health
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated:  1/25/2017
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated: 1/25/2017
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated:  1/25/2017
San Francisco General Hospital and Trauma Center
1339
mi
from
San Francisco, CA
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated: 1/25/2017
San Francisco General Hospital and Trauma Center
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated:  1/25/2017
Becton Dickinson MedLab
1344
mi
from
San Jose, CA
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated: 1/25/2017
Becton Dickinson MedLab
1344
mi
from
San Jose, CA
Click here to add this to my saved trials
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated:  1/25/2017
National AIDS Research Institute
821
mi
from
Pune,
Accuracy Evaluation of the BD FACS Presto System
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
Status: Enrolling
Updated: 1/25/2017
National AIDS Research Institute
821
mi
from
Pune,
Click here to add this to my saved trials
Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)
Evaluation of Rapid HIV Self-testing Among MSM in High Prevalence Cities
Status: Enrolling
Updated:  2/1/2017
Emory University
801
mi
from
Atlanta, GA
Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)
Evaluation of Rapid HIV Self-testing Among MSM in High Prevalence Cities
Status: Enrolling
Updated: 2/1/2017
Emory University
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated:  2/7/2017
Magee-Womens Hospital of UPMC
974
mi
from
Pittsburgh, PA
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated: 2/7/2017
Magee-Womens Hospital of UPMC
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated:  2/7/2017
Alabama CRS, 84519th Street South, BBRB 203A
683
mi
from
Birmingham, AL
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated: 2/7/2017
Alabama CRS, 84519th Street South, BBRB 203A
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated:  2/7/2017
Case CRS, Case Western Reserve University, 2061 Cornell Road, Room 303
894
mi
from
Cleveland, OH
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population
Status: Enrolling
Updated: 2/7/2017
Case CRS, Case Western Reserve University, 2061 Cornell Road, Room 303
894
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
Status: Enrolling
Updated:  2/9/2017
CARES Clinic
1283
mi
from
Sacramento, CA
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
Status: Enrolling
Updated: 2/9/2017
CARES Clinic
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Community AIDS Network
1142
mi
from
Sarasota, FL
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Community AIDS Network
1142
mi
from
Sarasota, FL
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Jacobi Medical Center
1295
mi
from
Bronx, NY
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Jacobi Medical Center
1295
mi
from
Bronx, NY
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Louisiana State University
697
mi
from
New Orleans, LA
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Louisiana State University
697
mi
from
New Orleans, LA
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Palmtree Clinical Research Inc
1082
mi
from
Palm Springs, CA
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Palmtree Clinical Research Inc
1082
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
UCSD - AnitViral Research Center (AVRC)
1142
mi
from
San Diego, CA
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
UCSD - AnitViral Research Center (AVRC)
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
University of Miami AIDS Clinical Research Unit
1320
mi
from
Miami, FL
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
University of Miami AIDS Clinical Research Unit
1320
mi
from
Miami, FL
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Wishard Health Services
643
mi
from
Indianapolis, IN
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Wishard Health Services
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated:  2/22/2017
Yale University
1344
mi
from
New Haven, CT
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
Status: Enrolling
Updated: 2/22/2017
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Director, Adolescent AIDS Program
1294
mi
from
Bronx, NY
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Director, Adolescent AIDS Program
1294
mi
from
Bronx, NY
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Mount Sinai Hospital
1289
mi
from
New York, NY
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Mount Sinai Hospital
1289
mi
from
New York, NY
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University of California, San Diego
1118
mi
from
San Diego, CA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University of California, San Diego
1118
mi
from
San Diego, CA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
1341
mi
from
San Francisco, CA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Children's Hospital National Medical Center
1127
mi
from
Washington,
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Children's Hospital National Medical Center
1127
mi
from
Washington,
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Children's Diag. & Treatment Ctr.
1308
mi
from
Fort Lauderdale, FL
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Children's Diag. & Treatment Ctr.
1308
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University of Miami
1319
mi
from
Miami, FL
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University of Miami
1319
mi
from
Miami, FL
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University of South Florida
1113
mi
from
Tampa, FL
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University of South Florida
1113
mi
from
Tampa, FL
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Stroger Hospital of Cook County
608
mi
from
Chicago, IL
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Stroger Hospital of Cook County
608
mi
from
Chicago, IL
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Tulane Medical Center
697
mi
from
New Orleans, LA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Tulane Medical Center
697
mi
from
New Orleans, LA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University of Maryland
1148
mi
from
Baltimore, MD
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University of Maryland
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
Children's Hospital Boston
1442
mi
from
Boston, MA
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
Children's Hospital Boston
1442
mi
from
Boston, MA
Click here to add this to my saved trials
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated:  2/27/2017
University Pediatric Hospital
6864
mi
from
San Juan,
C2P Mobilization Intervention (Pilot)
Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III
Status: Enrolling
Updated: 2/27/2017
University Pediatric Hospital
6864
mi
from
San Juan,
Click here to add this to my saved trials
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated:  2/27/2017
University of Colorado Denver
402
mi
from
Aurora, CO
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated: 2/27/2017
University of Colorado Denver
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated:  2/27/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated: 2/27/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated:  2/27/2017
The Fenway Institute-Fenway Health
1444
mi
from
Boston, MA
Managerial Database II
Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III
Status: Enrolling
Updated: 2/27/2017
The Fenway Institute-Fenway Health
1444
mi
from
Boston, MA
Click here to add this to my saved trials